Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:18:57.588Z.
Calculation as of: 2026-10-06T22:18:57.588Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69c6abe1898d62982c9f5472fcc208679ef9964d1dbc89e7ebe68f1e3eabf120
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2015-11-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$143.84M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.62M
PS Ratio
N/A
TTM Avg
636.97
3Y Avg
636.97
5Y Avg
636.97
Market Cap
$139.04M
PS Ratio
N/A
TTM Avg
129881.85
3Y Avg
50585.07
5Y Avg
50585.07
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | 5.46 | 16.79 | 41.83 | 132.05 |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 2.14 | 7.67 | 3.96 | 3.05 |
| Codexis, Inc. (CDXS)vs › | $146.28M | 1.88 | 2.61 | 3.23 | 4.75 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | 636.97 | 636.97 | 636.97 |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | 3.06 | 2.75 | 2.29 | 3.79 |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | 9.14 | 14.60 | 22.81 | 22.81 |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A | 129881.85 | 50585.07 | 50585.07 |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-10 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2015-11-12 | 80.94 |
| 2015-11-11 | 82.00 |
| 2015-11-10 | 83.45 |
| 2015-11-09 | 82.56 |
| 2015-11-06 | 82.28 |
| 2015-11-05 | 82.00 |
| 2015-11-04 | 82.06 |
| 2015-11-03 | 80.22 |
| 2015-11-02 | 80.44 |
| 2015-10-30 | 76.21 |
| 2015-10-29 | 76.44 |
| 2015-10-28 | 76.83 |
| 2015-10-27 | 76.94 |
| 2015-10-26 | 79.94 |
| 2015-10-23 | 82.95 |
| 2015-10-22 | 92.24 |
| 2015-10-21 | 92.40 |
| 2015-10-20 | 91.96 |
| 2015-10-19 | 87.28 |
| 2015-10-16 | 84.61 |
| 2015-10-15 | 82.83 |
| 2015-10-14 | 80.05 |
| 2015-10-13 | 81.83 |
| 2015-10-12 | 80.94 |
| 2015-10-09 | 80.78 |
| 2015-10-08 | 79.11 |
| 2015-10-07 | 81.28 |
| 2015-10-06 | 78.55 |
| 2015-10-05 | 81.89 |
| 2015-10-02 | 78.44 |
| 2015-10-01 | 73.49 |
| 2015-09-30 | 77.38 |
| 2015-09-29 | 72.65 |
| 2015-09-28 | 70.04 |
| 2015-09-25 | 75.82 |
| 2015-09-24 | 81.22 |
| 2015-09-23 | 80.00 |
| 2015-09-22 | 80.61 |
| 2015-09-21 | 80.78 |
| 2015-09-18 | 83.17 |
| 2015-09-17 | 84.00 |
| 2015-09-16 | 83.56 |
| 2015-09-15 | 85.00 |
| 2015-09-14 | 83.39 |
| 2015-09-11 | 82.95 |
| 2015-09-10 | 81.89 |
| 2015-09-09 | 76.99 |
| 2015-09-08 | 77.05 |
| 2015-09-04 | 77.10 |
| 2015-09-03 | 77.44 |
| 2015-09-02 | 81.94 |
| 2015-09-01 | 78.27 |
| 2015-08-31 | 78.83 |
| 2015-08-28 | 79.44 |
| 2015-08-27 | 75.71 |
| 2015-08-26 | 76.88 |
| 2015-08-25 | 72.10 |
| 2015-08-24 | 73.66 |
| 2015-08-21 | 76.88 |
| 2015-08-20 | 74.43 |
| 2015-08-19 | 75.27 |
| 2015-08-18 | 75.27 |
| 2015-08-17 | 78.16 |
| 2015-08-14 | 73.60 |
